Prolonged high‐dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis
2009; Wiley; Volume: 64; Issue: 9 Linguagem: Inglês
10.1111/j.1398-9995.2009.02045.x
ISSN1398-9995
AutoresKalliopi Kontou-Fili, Christos Filis,
Tópico(s)Urticaria and Related Conditions
ResumoAllergyVolume 64, Issue 9 p. 1384-1385 Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis K. Kontou-Fili, Corresponding Author K. Kontou-Fili *Chief Allergology DepartmentEuroclinic Hospital8 Fidippidou st. Athens 11526Hellas (Gr)AthensGreeceTel.: +30 2107774666; ++30 6932421516Fax: +30 2106010842Email: kontoufk@otenet.grSearch for more papers by this authorC. I. Filis, C. I. FilisSearch for more papers by this author K. Kontou-Fili, Corresponding Author K. Kontou-Fili *Chief Allergology DepartmentEuroclinic Hospital8 Fidippidou st. Athens 11526Hellas (Gr)AthensGreeceTel.: +30 2107774666; ++30 6932421516Fax: +30 2106010842Email: kontoufk@otenet.grSearch for more papers by this authorC. I. Filis, C. I. FilisSearch for more papers by this author First published: 14 September 2009 https://doi.org/10.1111/j.1398-9995.2009.02045.xCitations: 42 High Omalizumab dose, administered at strictly 30-day intervals, controls venom immunotherapy reactions in systemic mastocytosis. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article.Citing Literature Volume64, Issue9September 2009Pages 1384-1385 RelatedInformation
Referência(s)